focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.70
Bid: 32.40
Ask: 33.00
Change: -0.30 (-0.91%)
Spread: 0.60 (1.852%)
Open: 32.70
High: 32.70
Low: 32.70
Prev. Close: 33.00
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

25 Mar 2010 07:00

RNS Number : 1442J
China Real Estate Opportunities PLC
25 March 2010
 



 

 

 

China Real Estate Opportunities plc

 

Directors / PDMR Shareholding

 

In accordance with Rule 17 of the AIM Rules, China Real Estate Opportunities plc ("CREO" or the "Company") announces that on 24 March 2010 it was notified by various directors and a significant shareholder, as detailed below, of share purchases made as part of the recent placing by the Company announced on 23 March 2010. Following the completion of the buy back of 1,500,000 shares for cancellation announced on the same day, the issued share capital of the Company is 48,036,004.

 

Richard Barrett, a director of the Company, notified the Company that on 23 March 2010 he purchased 131,510 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.27 per cent of the issued share capital of the Company.

 

Following the share purchase, Richard Barrett has an interest in 8,955,518 ordinary no par value shares representing 18.64 per cent of the issued share capital of the Company.

 

In addition, the Company was notified by Mr Barrett that members of his family purchased 119,000 ordinary no par value shares representing 0.25 per cent of the issued share capital of the Company. Following the share purchase, members of Mr Barrett's family have an interest in 131,891 ordinary no par value shares representing 0.27 per cent of the issued share capital of the Company.

 

Rory Williams, a director of the Company, notified the Company that on 23 March 2010 he purchased 55,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.11 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr Williams has an interest in 175,000 ordinary no par value shares representing 0.36 per cent of the issued share capital of the Company.

 

Richard David, a director of the Company, notified the Company that on 23 March 2010 he purchased 17,500 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.04 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr David has an interest in 30,000 ordinary no par value shares representing 0.06 per cent of the issued share capital of the Company.

 

Ray Horney, a director of the Company, notified the Company that on 23 March 2010 Barclays Wealth Trustees (Guernsey) Limited, acting as Trustee of certain trusts under which Mr Horney and / or members of his family are beneficiaries, purchased 75,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.16 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr Horney has an interest in 2,825,000 ordinary no par value shares representing 5.88 per cent of the issued share capital of the Company.

 

In addition the Company was notified by Mr Horney that a member of his family purchased 45,000 ordinary no par value shares representing 0.09 per cent of the issued share capital of the Company. This purchase represents the total interest in the Company following the share purchase.

 

On the same day, the Company was notified by John Ronan, a significant shareholder of the Company and a 50 per cent shareholder of Treasury Holdings, that a member of his family purchased 55,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.11 per cent and represents their total interest in the Company following the share purchase.

 

 

 

 

 

 

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0) 1273 775 225

 

Sarah Moriarty, Investor Relations

Tel: + 353 1 618 9455

 

 

Matrix Corporate Capital LLP

Paul Fincham, Rob Naylor

Tel: + 44 (0) 20 3206 7000

 

 

Davy

Des Carville

Tel: +353 1 679 6363

 

 

Citigate Dewe Rogerson Limited 

Tom Baldock

Tel: 44 (0) 20 7638 9571

 

 

Murray Consultants

Ed Micheau

Tel: + 353 1 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFDVSISFII
Date   Source Headline
23rd Dec 20217:00 amRNSExercise of Options
30th Nov 20217:00 amRNSTotal Voting Rights
24th Nov 20217:00 amRNSExercise of Options
12th Nov 20217:00 amRNSAcquisition of Aber Electronics Limited
11th Nov 20217:00 amRNSAppointment of Joint Broker
30th Sep 202112:00 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSHalf-year Report
9th Sep 202111:23 amRNSDirector/PDMR Shareholding
8th Sep 20213:59 pmRNSHolding(s) in Company
16th Aug 20213:34 pmRNSOpen Offer Launch, Posting of Circular & GM Notice
13th Aug 20214:45 pmRNSResult of Placing
12th Aug 20215:37 pmRNSProposed Placing & Open Offer, Launch of ABB
30th Jul 20215:00 pmRNSTotal Voting Rights
20th Jul 20213:42 pmRNSShare Awards, Director Dealings & Issue of Equity
16th Jul 20217:00 amRNSOpening of United States East Coast Headquarters
1st Jul 20218:00 amRNSIssue of Equity
30th Jun 202110:30 amRNSResult of AGM
16th Jun 20217:00 amRNSMicroBlate Fine’s first in-human use update
14th Jun 20217:00 amRNSAcquisition of freehold site for £4.25m
4th Jun 20217:01 amRNSNotice of AGM
4th Jun 20217:00 amRNSFinal Results
26th May 20217:00 amRNSFurther health economics data validates technology
19th May 20217:00 amRNSTrading Update
30th Apr 20217:00 amRNSTotal Voting Rights
19th Apr 20217:00 amRNSExercise of Options
19th Feb 202111:31 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSTrading update
7th Jan 20217:00 amRNSUS FDA clearance for MicroBlate™ Flex device
9th Dec 202011:06 amRNSSecond Price Monitoring Extn
9th Dec 202011:00 amRNSPrice Monitoring Extension
9th Dec 20207:00 amRNSFirst clinical use of new Creo GI product
24th Nov 20201:36 pmRNSExercise of Options
3rd Nov 20207:00 amRNSAcquisition of Boucart Medical SRL
2nd Nov 20207:00 amRNSUS FDA clearance for MicroBlate™ Fine device
23rd Sep 20207:00 amRNSHalf-year Report
26th Aug 20204:09 pmRNSHolding(s) in Company
11th Aug 20207:00 amRNSExercise of Options
3rd Aug 20207:00 amRNSVideo abstract published endorsing Speedboat
24th Jul 202011:00 amRNSDirector/PDMR Shareholding
24th Jul 20207:00 amRNSAcquisition of Albyn Medical S.L.
13th Jul 202010:37 amRNSSecretary of State for Wales site visit
13th Jul 202010:08 amRNSSecretary of State for Wales site visit
6th Jul 20207:00 amRNSDirectorate Change
2nd Jul 20207:00 amRNSDevelopment loan for plasma sterilising product
24th Jun 202010:30 amRNSResult of AGM
15th Jun 20207:00 amRNSCE mark for five new devices
8th Jun 20207:00 amRNSIET Prize nomination
3rd Jun 20207:00 amRNSPositive NHS health economics data
27th May 20207:00 amRNSPosting of Annual Report & Notice of AGM
20th May 20207:00 amRNSCommercialisation Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.